Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.
Pyoderma gangrenosum (PG) is a rare inflammatory and ulcerative skin disorder that is often associated with an underlying systemic disease, including inflammatory bowel disease. Many treatments used to treat inflammatory bowel disease are also used for the treatment of PG, including systemic therapi...
| Publicado en: | ACG Case Reports Journal Vol. 11; no. 10; pp. 1 - 5 |
|---|---|
| Autores principales: | , , , |
| Formato: | case study diagnostic images pictorial tables/charts Journal Article |
| Publicado: |
American College of Gastroenterology
Oct2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180791552&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 180791552 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23263253 HJC2 jtl: ACG Case Reports Journal issn: 23263253 maglogo: N pubinfo: dt: Oct2024 vid: 11 iid: 10 pid: 94678 pub: American College of Gastroenterology place: Bethesda, Maryland artinfo: ui: 180791552 180791552 180791552 10.14309/crj.0000000000001531 180791552 ppf: 1 ppct: 4 formats: tig: atl: Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib. aug: au: Park, Sarah St Pierre, Joelle Onajin, Oluwakemi Rubin, David T. affil: University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL sug: subj: Pyoderma Gangrenosum Drug Therapy Severity of Illness Colitis, Ulcerative Drug Therapy Janus Kinase Inhibitors Therapeutic Use Dermatologic Agents Therapeutic Use Antiulcer Agents Therapeutic Use Antiinflammatory Agents Therapeutic Use Treatment Outcomes Female Middle Age Steroids Treatment Failure Immunologic Factors Tumor Necrosis Factor Inhibitors Drug Efficacy Middle Aged: 45-64 years Female ab: Pyoderma gangrenosum (PG) is a rare inflammatory and ulcerative skin disorder that is often associated with an underlying systemic disease, including inflammatory bowel disease. Many treatments used to treat inflammatory bowel disease are also used for the treatment of PG, including systemic therapies, immunomodulators, and tumor necrosis factor-a inhibitors; however, their efficacy in PG is limited. Novel treatments of PG are needed. We report the case of a 62-year-old woman with steroid-refractory PG and concomitant ulcerative colitis successfully treated for both conditions with upadacitinib, a selective Janus kinase inhibitor. pubtype: Academic Journal doctype: case study diagnostic images pictorial tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|